Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models

Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models

Background Concurrent KRAS LKB1 (STK11, KL) mutant non-small cell lung cancers (NSCLC) do not respond well to current immune checkpoint blockade therapies, however targeting major histocompatibility complex class I-related chain A or B (MICA/B), could pose an alternative therapeutic strategy through...

Full description

Saved in:
Bibliographic Details
Main Authors: Shohei Koyama, Yujiro Naito, John D Minna, David E Gerber, Ryan R Kowash, Manoj Sabnani, Laura T Gray, Qing Deng, Nusrat U A Saleh, Luc Girard, Kentaro Masahiro, Zhiqian Lucy Liu, Hemanta Baruah, Esra A Akbay
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e009867.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/1/e009867.full

Similar Items